This review met 12 and partly met one of the 16 relevant AMSTAR criteria and found no significant difference in efficacy of stroke prevention, between each direct OAC and genotype-guided warfarin dosing (the gene was not specified, but references indicated it was CYP2C9). The gene discussed is CYP2C9; the disease is stroke disorder.